Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5972-5978

  Treviño, Lisa R ^a   Shimasaki, Noriko ^a   Yang, Wenjian ^a   Panetta, John C ^a   Cheng, Cheng ^a   Pei, Deqing ^a   Chan, Diana ^a   Sparreboom, Alex ^a   Giacomini, Kathleen M ^a   Pui, Ching Hon ^a   Evans, William E ^a   Relling, Mary V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; SLCO1B1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; COHORT ANALYSIS; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFECT; EVENING DOSAGE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; INFANT; METABOLISM; MUTATION; PHENOTYPE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; INFANT; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; METHOTREXATE; ORGANIC ANION TRANSPORTERS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 73349098768     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.4156     Document Type: Article

References (59)

1. Gudmundsson J, Sulem P, Steinthorsdottir V, et al: Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977-983, 2007
2. Hakonarson H, Grant SF, Bradfield JP, et al: A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448:591-594, 2007
3. McPherson R, Pertsemlidis A, Kavaslar N, et al: A common allele on chromosome 9 associated with coronary heart disease. Science 316:1488-1491, 2007
4. Samani NJ, Erdmann J, Hall AS, et al: Genomewide association analysis of coronary artery disease. N Engl J Med 357:443-453, 2007
5. Yeager M, Orr N, Hayes RB, et al: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645-649, 2007
6. Goldstein DB: Pharmacogenetics in the laboratory and the clinic. N Engl J Med 348:553-556, 2003
7. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538-549, 2003
8. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004
9. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671, 2000
10. Roden DM, Altman RB, Benowitz NL, et al: Pharmacogenomics: Challenges and opportunities. Ann Intern Med 145:749-757, 2006
11. Jolivet J, Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094-1104, 1983
12. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 350:1535-1548, 2004
13. Olsen NJ, Stein CM: New drugs for rheumatoid arthritis. N Engl J Med 350:2167-2179, 2004
14. Wessels JA, van der Kooij SM, le Cessie S, et al: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56:1765-1775, 2007
15. Niemeyer CM, Gelber RD, Tarbell NJ, et al: Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood 78:2514-2519, 1991
16. Evans WE, Crom WR, Stewart CF, et al: Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1:359-362, 1984
17. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471-477, 1986
18. Camitta B, Leventhal B, Lauer S, et al: Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 7:1539-1544, 1989
19. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
20. Abelson HT, Fosburg MT, Beardsley GP, et al: Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208-216, 1983
21. Jaffe N, Gorlick R: High-dose methotrexate in osteosarcoma: Let the questions surcease-time for final acceptance. J Clin Oncol 26:4365-4366, 2008
22. Relling MV, Fairclough D, Ayers D, et al: Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667-1672, 1994
23. Woessmann W, Seidemann K, Mann G, et al: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948-958, 2005
24. Laverdière C, Chiasson S, Costea I, et al: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832-3834, 2002
25. de Jonge R, Hooijberg JH, van Zelst BD, et al: Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106:717-720, 2005
26. Kishi S, Cheng C, French D, et al: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109:4151-4157, 2007
27. Pui CH, Sandlund JT, Pei D, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104:2690-2696, 2004
28. Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
29. Kishi S, Griener J, Cheng C, et al: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21:3084-3091, 2003
30. Pauley JL, Panetta JC, Schmidt J, et al: Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol 54:146-152, 2004
31. Scheet P, Stephens M: A fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 78:629-644, 2006
32. Price AL, Patterson NJ, Plenge RM, et al: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904-909, 2006
33. Pinheiro JC, Bates DM: Mixed-Effects Models in S and S-Plus. 2000
34. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals Stat 16:1141-1154, 1988
35. Krajinovic M, Moghrabi A: Pharmacogenetics of methotrexate. Pharmacogenomics 5:819-834, 2004
36. Ansari M, Krajinovic M: Pharmacogenomics in cancer treatment defining genetic bases for interindividual differences in responses to chemotherapy. Curr Opin Pediatr 19:15-22, 2007
37. Cheok MH, Evans WE: Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy 2. Nat Rev Cancer 6:117-129, 2006
38. Kager L, Evans WE: Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol 13:260-265, 2006
39. Abe T, Kakyo M, Tokui T, et al: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274: 17159-17163, 1999
40. Marzolini C, Tirona RG, Gervasini G, et al: A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression 10. Mol Endocrinol 21:1769-1780, 2007
41. Glaeser H, Bailey DG, Dresser GK, et al: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362-370, 2007
42. Abe T, Unno M, Onogawa T, et al: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120:1689-1699, 2001
43. Tirona RG, Leake BF, Merino G, et al: Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675, 2001
44. Niemi M, Schaeffeler E, Lang T, et al: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440, 2004
45. Pasanen MK, Neuvonen M, Neuvonen PJ, et al: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879, 2006
46. Liu L, Cui Y, Chung AY, et al: Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 318:395-402, 2006
47. Nozawa T, Minami H, Sugiura S, et al: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439, 2005
48. Kameyama Y, Yamashita K, Kobayashi K, et al: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+ C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522, 2005
49. Pasanen MK, Fredrikson H, Neuvonen PJ, et al: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726-733, 2007
50. Ho RH, Choi L, Lee W, et al: Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 17:647-656, 2007
51. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802, 2007
52. Egan LJ, Sandborn WJ, Mays DC, et al: Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther 65:29-39, 1999
53. Evans WE, Tsiatis A, Crom WR, et al: Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. J Pharm Sci 70:1194-1198, 1981
54. Connell WR, Kamm MA, Ritchie JK, et al: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34:1081-1085, 1993
55. Present DH, Meltzer SJ, Krumholz MP, et al: 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 111:641-649, 1989
56. Murry DJ, Synold TW, Pui CH, et al: Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy 15:144-149, 1995
57. Cohen JC, Boerwinkle E, Mosley TH Jr, et al: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006
58. Fotoohi K, Jansen G, Assaraf YG, et al: Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy. Blood 104:4194-4201, 2004
59. Badagnani I, Castro RA, Taylor TR, et al: Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521-529, 2006